##semicolon##
хроническая сердечная недостаточность, ожирение, кардиометаболический профиль, кардиометаболическое фенотипирование, кардиометаболическая дисфункция, метаболический синдром, инсулинорезистентность, стратификация риска, персонализированная медицина.##submission.citations##
1. McDonagh TA, Metra M, Adamo M, Gardner RS, Baumbach A, Böhm M, et al. 2023 Focused update of the 2021 ESC Guidelines for the diagnosis and treatment of acute and chronic heart failure. Eur Heart J. 2023;44(37):3627-3639.
2. Heidenreich PA, Bozkurt B, Aguilar D, Allen LA, Byun JJ, Colvin MM, et al. 2022 AHA/ACC/HFSA Guideline for the Management of Heart Failure. Circulation. 2022;145(18):e895-e1032.
3. Packer M. Epicardial adipose tissue may mediate deleterious effects of obesity and inflammation on the myocardium. JACC Heart Fail. 2021;9(8): 584-593.
4. Lavie CJ, Pandey A, Lau DH, Alpert MA, Sanders P. Obesity and atrial fibrillation prevalence, pathogenesis, and prognosis. J Am Coll Cardiol. 2023; 81(9):890-907.
5. Verma S, McMurray JJV. The serendipitous story of SGLT2 inhibitors in heart failure. Circulation. 2022;145(16):1171-1175.
6. Anker SD, Butler J, Filippatos G, Ferreira JP, Bocchi E, Böhm M, et al. Empagliflozin in heart failure with a preserved ejection fraction. N Engl J Med. 2021;385(16):1451-1461.
7. Packer M, Butler J, Filippatos G, Ferreira JP, Zannad F. Mechanisms of benefit of SGLT2 inhibitors in heart failure. Eur Heart J. 2023;44(5):415-426.
8. Zannad F, Ferreira JP, Pocock SJ, Zeller C, Anker SD, Butler J, et al. Cardiac and kidney benefits of empagliflozin in heart failure. Circulation. 2022; 145(2):120-132.
9. Cooper LB, Hammill BG, Sharma PP, et al. Inflammation and heart failure: emerging concepts and therapeutic implications. J Am Coll Cardiol. 2021; 77(15):1916-1931.
10. Paulus WJ, Tschöpe C. A novel paradigm for heart failure with preserved ejection fraction. J Am Coll Cardiol. 2021;77(23):3004-3015.
11. Powell-Wiley TM, Poirier P, Burke LE, Després JP, Gordon-Larsen P, Lavie CJ, et al. Obesity and cardiovascular disease: a scientific statement from the American Heart Association. Circulation. 2021;143(21):e984-e1010.
12. Neeland IJ, Poirier P, Després JP. Cardiovascular and metabolic heterogeneity of obesity. Circulation. 2023;147(2):139-153.
13. Mechanick JI, Farkouh ME, Newman JD, Garvey WT. Cardiometabolic-based chronic disease, adiposity and dysglycemia drivers. J Am Coll Cardiol. 2020;75(5):525-538.
14. Després JP. Visceral obesity, insulin resistance and cardiovascular disease. Eur Heart J. 2022;43(34):3241-3248.
15. Engin A. The definition and prevalence of obesity and metabolic syndrome. Adv Exp Med Biol. 2021;960:1-17.
16. Ouchi N, Parker JL, Lugus JJ, Walsh K. Adipokines in inflammation and metabolic disease. Nat Rev Immunol. 2022;22(2):85-97.
17. Stern JH, Rutkowski JM, Scherer PE. Adiponectin, leptin and adipose tissue biology in cardiometabolic disease. Circ Res. 2021;128(2):181-201.
18. Frühbeck G, Busetto L, Dicker D, Yumuk V, Goossens GH, Hebebrand J, et al. The ABCD of obesity: an EASO position statement. Obes Facts. 2022;15(2):171-178.
19. Fernández-Real JM, Pickup JC. Innate immunity, inflammation and metabolic syndrome. Diabetologia. 2021;64(5):1037-1048.
20. Packer M. Leptin-aldosterone-neprilysin axis and cardiometabolic disease. Eur J Heart Fail. 2022;24(8):1291-1302.
21. Dunlay SM, Givertz MM, Aguilar D, Allen LA, Chan M, Desai AS, et al. Type 2 diabetes mellitus and heart failure: a scientific statement from the American Heart Association. Circulation. 2022;145 (7): e251-e272.
22. Seferović PM, Vardas P, Jankowska EA, Maggioni AP, Timmis A, Milinković I, et al. The Heart Failure Association Atlas: heart failure epidemiology and phenotype diversity. Eur J Heart Fail. 2023;25 (1):4-18.
23. Bozkurt B, Coats AJS, Tsutsui H, Abdelhamid M, Adamopoulos S, Albert N, et al. Universal definition and classification of heart failure. Eur J Heart Fail. 2021;23(3):352-380.
24. Pandey A, Patel KV, Lavie CJ. Obesity, metabolic dysfunction and heart failure. Prog Cardiovasc Dis. 2022;70:62-71.
25. Rosenzweig JL, Ferrannini E, Grundy SM, Haffner SM, Heine RJ, Horton ES, et al. Primary prevention of cardiovascular disease and type 2 diabetes in patients with metabolic risk. Circulation. 2021; 143(7):e307-e318.